AN OPEN-LABEL, MULTICENTER PHASE 1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF RO7296682 IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS
- Registry ID
- BP42595
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- HOFFMANN-LA ROCHE LIMITED
- Start date
- 2022-04-26
- Last update
- 2020-12-03
Conditions
Related clinical trials
- AN OPEN-LABEL, PHASE I/II FIRST IN HUMAN, DOSE ESCALATION, OPTIMISATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY AND ANTI-TUMOR ACTIVITY OF IPN01203 IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WHO HAVE PROGRESSED ON OR AFTER IMMUNE CHECKPOINT INHIBITOR THERAPIES
- A PHASE 1B/2, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY
AND SAFETY OF GSK5764227 ALONE AND IN COMBINATION IN PARTICIPANTS WITH
PREVIOUSLY TREATED ADVANCED UNRESECTABLE OR METASTATIC GASTROINTESTINAL SOLID
TUMORS
- A PHASE 1 OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MK-4700 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
- A PHASE 2 OPEN-LABEL BASKET STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED REVERSIBLE TYROSINE KINASE INHIBITOR BAY 2927088 IN PARTICIPANTS WITH METASTATIC OR UNRESECTABLE SOLID TUMORS WITH HER2-ACTIVATING MUTATIONS
- A PHASE IA/IB DOSE-ESCALATION AND DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC 6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION
- AN OPEN LABEL, MULTICENTER, RANDOMIZED DOSE-ESCALATION AND EXTENSION, PHASE IA/IB STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF RO7284755, A PD-1 TARGETED IL-2 VARIANT (IL-2V) IMMUNOCYTOKINE, ALONE OR IN COMBINATION WITH ATEZOLIZUMAB IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS
View on source registry